This study is accepting new patients by invitation only
CY 6022 is an Open Label Study to Collect Long-term Safety and Tolerability Data for Aficamten (CK-3773274)
Summary
- Eligibility
- for people ages 18-85 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients by invitation only
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Cytokinetics
- ID
- NCT04848506
- Phase
- Phase 2 Cardiomyopathy Research Study
- Study Type
- Interventional
- Participants
- Expecting 600 study participants
- Last Updated